MX2020009262A - Vectores de parapoxvirus. - Google Patents
Vectores de parapoxvirus.Info
- Publication number
- MX2020009262A MX2020009262A MX2020009262A MX2020009262A MX2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A
- Authority
- MX
- Mexico
- Prior art keywords
- pcpv
- provides
- present
- diseases
- pvpv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24241—Use of virus, viral particle or viral elements as a vector
- C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305237 | 2018-03-07 | ||
| EP18306424 | 2018-10-31 | ||
| PCT/EP2019/055744 WO2019170820A1 (en) | 2018-03-07 | 2019-03-07 | Parapoxvirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009262A true MX2020009262A (es) | 2021-01-08 |
Family
ID=65628796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009262A MX2020009262A (es) | 2018-03-07 | 2019-03-07 | Vectores de parapoxvirus. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12377142B2 (https=) |
| EP (1) | EP3762020A1 (https=) |
| JP (2) | JP2021516957A (https=) |
| CN (1) | CN112512560A (https=) |
| AU (1) | AU2019229653B2 (https=) |
| BR (1) | BR112020018117A2 (https=) |
| CA (1) | CA3093093A1 (https=) |
| IL (1) | IL277161A (https=) |
| MX (1) | MX2020009262A (https=) |
| WO (1) | WO2019170820A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021258008A1 (en) * | 2020-06-19 | 2021-12-23 | Immunacor Llc | Compositions and methods for treating and preventing viral infection |
| WO2023083951A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN116121207B (zh) * | 2023-02-08 | 2025-12-12 | 华南农业大学 | 一种表达猪圆环病毒3型Cap蛋白的重组羊口疮病毒及其制备方法和应用 |
| WO2024178260A2 (en) * | 2023-02-22 | 2024-08-29 | Cornell University | Systems and methods for heterologous gene expression by poxvirus vectors |
| CN116897887A (zh) * | 2023-07-31 | 2023-10-20 | 湖南中医药大学 | 一种病毒性哮喘动物模型的构建方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054438A (en) | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| JP2000507092A (ja) * | 1996-02-28 | 2000-06-13 | バイエル・アクチエンゲゼルシヤフト | 外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用 |
| KR20000005120A (ko) | 1996-03-29 | 2000-01-25 | 스칸드레트 존 디 | 파라폭스바이러스 벡터 |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| JP2003523320A (ja) | 1999-09-29 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途 |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| CA2467365C (en) | 2001-12-10 | 2012-11-20 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| EP2481819A1 (en) | 2003-02-25 | 2012-08-01 | MedImmune Vaccines, Inc. | Cross flow filtration in the production of stabilized influenza vaccine compositions |
| JP4672659B2 (ja) | 2003-07-21 | 2011-04-20 | トランジェーヌ、ソシエテ、アノニム | 改善されたシトシンデアミナーゼ活性を有するポリペプチド |
| CN1984666A (zh) | 2004-07-13 | 2007-06-20 | 爱库里斯股份有限两合公司 | 与其他抗病毒剂联合治疗hiv/aids的副痘病毒 |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| DK2029756T3 (en) * | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| PT103865A (pt) | 2007-10-25 | 2009-05-15 | Univ De Coimbra | Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção |
| RU2503717C2 (ru) | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| US9222078B2 (en) | 2010-07-01 | 2015-12-29 | Novozymes A/S | Bleaching of pulp |
| AU2011281229A1 (en) | 2010-07-20 | 2013-01-24 | Zoetis Llc | Parapoxvirus vectors |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| KR102507483B1 (ko) | 2014-12-01 | 2023-03-07 | 트랜스진 | 안정한 액체 백시니아 바이러스 제제 |
| EP4523756A3 (en) * | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| DE102015111756A1 (de) * | 2015-07-20 | 2017-01-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Rekombinanter Orf-Virus-Vektor |
| KR20230113832A (ko) * | 2016-08-09 | 2023-08-01 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
-
2019
- 2019-03-07 CA CA3093093A patent/CA3093093A1/en active Pending
- 2019-03-07 BR BR112020018117-0A patent/BR112020018117A2/pt unknown
- 2019-03-07 CN CN201980030479.4A patent/CN112512560A/zh active Pending
- 2019-03-07 EP EP19708331.4A patent/EP3762020A1/en active Pending
- 2019-03-07 MX MX2020009262A patent/MX2020009262A/es unknown
- 2019-03-07 WO PCT/EP2019/055744 patent/WO2019170820A1/en not_active Ceased
- 2019-03-07 JP JP2020546320A patent/JP2021516957A/ja active Pending
- 2019-03-07 US US16/978,219 patent/US12377142B2/en active Active
- 2019-03-07 AU AU2019229653A patent/AU2019229653B2/en active Active
-
2020
- 2020-09-06 IL IL277161A patent/IL277161A/en unknown
-
2024
- 2024-01-09 JP JP2024001510A patent/JP2024050588A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210000937A1 (en) | 2021-01-07 |
| AU2019229653B2 (en) | 2025-09-11 |
| WO2019170820A9 (en) | 2020-05-28 |
| JP2021516957A (ja) | 2021-07-15 |
| WO2019170820A1 (en) | 2019-09-12 |
| BR112020018117A2 (pt) | 2020-12-22 |
| CA3093093A1 (en) | 2019-09-12 |
| EP3762020A1 (en) | 2021-01-13 |
| US12377142B2 (en) | 2025-08-05 |
| AU2019229653A1 (en) | 2020-09-24 |
| CN112512560A (zh) | 2021-03-16 |
| IL277161A (en) | 2020-10-29 |
| JP2024050588A (ja) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009262A (es) | Vectores de parapoxvirus. | |
| EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| MX2022003658A (es) | Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb. | |
| MX2023008067A (es) | Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| WO2022140364A3 (en) | African swine fever (asf) virus vaccines | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| MX377531B (es) | Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón. | |
| MX2021014771A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. | |
| JOP20210186A1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| EP4043031A3 (en) | Zika viral antigen constructs | |
| IL280145A (en) | Methods and compositions using recombinant dendritic cells for cancer therapy | |
| EA202091516A1 (ru) | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) | |
| EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| EA201891601A1 (ru) | Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| MX2022000879A (es) | Vacuna viral terapeutica. | |
| EA201891287A1 (ru) | Вакцинация с использованием альфа 3-домена mica/b для лечения рака | |
| WO2020036646A3 (en) | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy | |
| PH12021550661A1 (en) | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy | |
| MX2021007860A (es) | Poxvirux deficiente en m2. | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| MX2023000734A (es) | Virus vaccinia recombinante. |